TY - JOUR
T1 - Modeling Ductal Carcinoma In Situ (DCIS)
T2 - An Overview of CISNET Model Approaches
AU - van Ravesteyn, Nicolien T.
AU - van den Broek, Jeroen J.
AU - Li, Xiaoxue
AU - Weedon-Fekjær, Harald
AU - Schechter, Clyde B.
AU - Alagoz, Oguzhan
AU - Huang, Xuelin
AU - Weaver, Donald L.
AU - Burnside, Elizabeth S.
AU - Punglia, Rinaa S.
AU - de Koning, Harry J.
AU - Lee, Sandra J.
N1 - Funding Information:
Department of Public Health, Erasmus MC, University Medical Center, Rotterdam, the Netherlands (NTV, JJV, HJD); Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA (XL); Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, USA (XL, SJL); Center for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital, Oslo, Norway (HW); Departments of Family and Social Medicine and Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA (CBS); Department of Industrial and Systems Engineering, University of Wisconsin-Madison, Madison, WI, USA (OA); Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, USA (XH); Department of Pathology and Laboratory Medicine, University of Vermont, Burlington, VT, USA (DLW); Department of Radiology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA (ESB); Department of Radiation Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA (RSP); and Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA (SJL). This work was supported by the National Institutes of Health under National Cancer Institute Grants U01CA152958 and U01CA199218. ESB was funded in part by National Institutes of Health grant R01CA165229.
Publisher Copyright:
© 2017, © The Author(s) 2017.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Background. Ductal carcinoma in situ (DCIS) can be a precursor to invasive breast cancer. Since the advent of screening mammography in the 1980’s, the incidence of DCIS has increased dramatically. The value of screen detection and treatment of DCIS, however, is a matter of controversy, as it is unclear the extent to which detection and treatment of DCIS prevents invasive disease and reduces breast cancer mortality. The aim of this paper is to provide an overview of existing Cancer Intervention and Surveillance Modelling Network (CISNET) modeling approaches for the natural history of DCIS, and to compare these to other modeling approaches reported in the literature. Design. Five of the 6 CISNET models currently include DCIS. Most models assume that some, but not all, lesions progress to invasive cancer. The natural history of DCIS cannot be directly observed and the CISNET models differ in their assumptions and in the data sources used to estimate the DCIS model parameters. Results. These model differences translate into variation in outcomes, such as the amount of overdiagnosis of DCIS, with estimates ranging from 34% to 72% for biennial screening from ages 50 to 74 y. The other models described in the literature also report a large range in outcomes, with progression rates varying from 20% to 91%. Limitations. DCIS grade was not yet included in the CISNET models. Conclusion. In the future, DCIS data by grade from active surveillance trials, the development of predictive markers of progression probability, and evidence from other screening modalities, such as tomosynthesis, may be used to inform and improve the models’ representation of DCIS, and might lead to convergence of the model estimates. Until then, the CISNET model results consistently show a considerable amount of overdiagnosis of DCIS, supporting the safety and value of observational trials for low-risk DCIS.
AB - Background. Ductal carcinoma in situ (DCIS) can be a precursor to invasive breast cancer. Since the advent of screening mammography in the 1980’s, the incidence of DCIS has increased dramatically. The value of screen detection and treatment of DCIS, however, is a matter of controversy, as it is unclear the extent to which detection and treatment of DCIS prevents invasive disease and reduces breast cancer mortality. The aim of this paper is to provide an overview of existing Cancer Intervention and Surveillance Modelling Network (CISNET) modeling approaches for the natural history of DCIS, and to compare these to other modeling approaches reported in the literature. Design. Five of the 6 CISNET models currently include DCIS. Most models assume that some, but not all, lesions progress to invasive cancer. The natural history of DCIS cannot be directly observed and the CISNET models differ in their assumptions and in the data sources used to estimate the DCIS model parameters. Results. These model differences translate into variation in outcomes, such as the amount of overdiagnosis of DCIS, with estimates ranging from 34% to 72% for biennial screening from ages 50 to 74 y. The other models described in the literature also report a large range in outcomes, with progression rates varying from 20% to 91%. Limitations. DCIS grade was not yet included in the CISNET models. Conclusion. In the future, DCIS data by grade from active surveillance trials, the development of predictive markers of progression probability, and evidence from other screening modalities, such as tomosynthesis, may be used to inform and improve the models’ representation of DCIS, and might lead to convergence of the model estimates. Until then, the CISNET model results consistently show a considerable amount of overdiagnosis of DCIS, supporting the safety and value of observational trials for low-risk DCIS.
KW - Cancer simulation
KW - breast cancer epidemiology
KW - ductal carcinoma in situ
KW - simulation models
UR - http://www.scopus.com/inward/record.url?scp=85044310850&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044310850&partnerID=8YFLogxK
U2 - 10.1177/0272989X17729358
DO - 10.1177/0272989X17729358
M3 - Article
C2 - 29554463
AN - SCOPUS:85044310850
SN - 0272-989X
VL - 38
SP - 126S-139S
JO - Medical Decision Making
JF - Medical Decision Making
IS - 1_suppl
ER -